Article by PDCI Market Access featured in TELUS Health Insights Magazine Members of the PDCI Team recently published an article and case study highlighting the risks to Canadian drug launches posed by Health Canada’s proposed Patented Medicines Prices Review Board (PMPRB) price regulatory reforms. This article, which appears in the Spring ...
PDCI Research Identifies Opportunities for Reimbursement of Nicotine Replacement Therapies under Employer Health Plans
Private health plans in Canada continue to implement many changes in their design and use of technology aimed at balancing the containment of health expenditures with the improvement of health and wellness. Yet what may be lost in any focus on cost-containment initiatives, is the opportunity for better management of ...
Proposed Amendments To The Patented Medicines Regulations: A Critical Appraisal Of The Cost-Benefit Analysis
In December 2017, the Governor-in-Council published in Canada Gazette Part 1 the most comprehensive changes affecting patented medicines since Bill C-91 was passed by the Government of Canada more than 25 years ago. These regulatory changes proposed by Health Canada are anticipated to have significant detrimental effects for Canadians and ...
The release of the Patented Medicine Prices Review Board (PMPRB) Annual Report is delayed once again this year - so much for transparency and the PMPRB’s mission statement to “provide stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement ...
Private Payer Product Listing Agreements in Canada – Second Joint Industry/Payer Survey Results – NOW AVAILABLE
Owing to new developments and growing stakeholder interest, PDCI and H3 have now completed a second private payer PLA survey. In total, 30 complete responses were received from 25 individual pharmaceutical companies and five different private payer representatives. With more respondents this year from manufacturers and representation from private payers, ...
PHARMACARE COSTING IN CANADA Estimated Costs of Proposed National Pharmacare Programs. Full report available here.
The objective of this preliminary report is to summarize PDCI’s assessment of the national pharmacare cost estimate study (Morgan et al) and identify some alternative mechanisms by which drug coverage in Canada can fulfill the spirit of the Canada Health Act plus the objectives of equity and sustainability. The final ...
Report 4: PLA Perspectives, Comparison and Contrast Last week Manulife introduced its new DrugWatch™. It has been described by Manulife as the only program of its kind in Canada which “closely monitors the drug landscape and analyzes the effectiveness and financial impact of new medications, to ensure you receive value ...
Report 3: Experience Negotiating Private Payer PLAs PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this survey, which was conducted ...
Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this ...